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OBJECTIVES The aim of this study was to evaluate the use of endovascular stents in native and recurrent
coarctation of the aorta (CoA).
BACKGROUND Stents have been used successfully in various locations. Their use in CoA can be an alternative
to surgery or balloon angioplasty (BA).
METHODS Thirty-four patients with CoA (13 native and 21 re-coarctation after surgery or BA) with a
mean age of 16  8 years (range 4 to 36 years) underwent attempted stent implantation
between 1993 and 1999. Successful outcome was defined as peak systolic pressure gradient
after stent implantation 20 mm Hg.
RESULTS Stents were implanted in 33/34 patients, and successful outcome occurred in 32/33 patients.
Peak systolic pressure gradient decreased from 32  12 mm Hg to 4  11 mm Hg (p 
0.001). Coarctation site to descending aorta diameter ratio increased from 0.46  0.16 to
0.92  0.16 (p  0.001). Two patients underwent successful stent re-dilation 16 and 21
months after initial implantation. Six patients (18%) developed complications, including two
patients who underwent surgery. Follow-up for 29  17 months (range: 5 to 81 months)
demonstrated no evidence of re-coarctation, aneurysm formation, stent displacement or
fracture. Systolic blood pressure (SBP) decreased from 136  21 mm Hg before stent
placement to 122  19 mm Hg at follow-up (p  0.002). The SBP gradient decreased from
39  18 mm Hg to 4  6 mm Hg, and peak Doppler gradient decreased from 51 
26 mm Hg to 13  11 mm Hg at follow-up (p  0.001).
CONCLUSIONS Intravascular stent placement for native and recurrent CoA has excellent results in the short
and intermediate terms. Long-term outcome remains to be evaluated. (J Am Coll Cardiol
2001;38:1518–23) © 2001 by the American College of Cardiology
Balloon-expandable endovascular stents have been used
successfully in the treatment of stenotic large vessels in
various locations in humans (1–7) and in animal models of
coarctation of the aorta (CoA) (8). We report our experi-
ence in using such stents for patients with native or
recurrent CoA, including both discrete and long-segment
obstruction, and offer this approach as an alternative to
surgery or balloon angioplasty (BA).
See page 1524
METHODS
Protocol. This study was performed in compliance with
the regulations of the Human Investigation Committee of
our institution. As this was a retrospective study, data
regarding patients’ clinical status were collected by chart
review. No tests were performed on any of the subjects as
part of the study protocol. Patient confidentiality was
maintained during data analysis and manuscript prepara-
tion.
Definition. Coarctation of the aorta was defined as systolic
arm-to-leg blood pressure gradient 20 mm Hg or echo-
cardiographic, magnetic resonance imaging (MRI) or an-
giographic evidence of CoA. Isthmus or transverse aortic
arch (TAR) hypoplasia was defined as a ratio of the
diameter of these structures to the descending aorta (DAo)
at the level of the diaphragm 0.6 (9–11). Successful
outcome was defined as a peak systolic residual gradient
after stent implantation of 20 mm Hg.
Patients. Thirty-four consecutive patients with CoA un-
derwent cardiac catheterization with the intention to treat
by stent implantation at our institution between May 1993
and July 1999. Characteristics of the patients and of the
CoA are summarized in Tables 1 and 2. The results of six
patients were previously reported (3). Eighteen patients
(53%) had discrete coarctation, and 16 (47%) patients had
tubular coarctation.
Technique of stent implantation. The technique of stent
implantation has been well described (3). After informed
consent, access was obtained via a femoral artery and vein.
General anesthesia was used in all but one patient who
required conscious sedation. Anticoagulation with heparin
was maintained to keep the activated clotting time 220 s
throughout the procedure. A complete hemodynamic study
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was performed crossing the coarctation site in a retrograde
manner before biplane angiography, and the appropriate
measurements were obtained. A long trans-septal sheath
was advanced over a guide wire across the coarctation site,
positioning the tip of the wire either in the left or right
subclavian artery. In 33 patients, we used either a Palmaz
308 or 188 stent (Johnson & Johnson Interventional Sys-
tem, Somerville, New Jersey). In one patient, a 28 CP stent
(NuMED Inc., Nicholville, New York) was implanted. The
stent was mounted and crimped onto a balloon catheter.
The diameter of the first balloon was chosen to be at least
twice the diameter of the coarctation site in order to
stabilize the position of the stent before using larger
balloons. The initial smaller balloon with the stent mounted
on it required a smaller sheath than the larger balloons used
subsequently. In 23 patients, at least two balloons were
required to expand the stent to its final diameter. Larger
balloons were also used to flare the ends of the stent to
oppose the aortic wall in patients with post-stenotic aortic
dilation to allow complete endothelization of the stent. The
combination of high pressure (HP) and low pressure (LP)
balloons used included: Z-Med and Tyshak balloons (B.
Braun Medical Inc., Bethlehem, Pennsylvania), Meditech
balloons (XXL, Black Diamond, Blue Max; Boston Scien-
tific Corp., Watertown, Massachusetts), as well as balloon-
in-balloon (BIB, NuMED Inc.). Repeat angiography and
pressure measurements were performed after stent implan-
tation.
Before discharge, all patients underwent complete clinical
evaluation, echocardiography and chest films. The patients
were placed on antiplatelet therapy with aspirin for three to
six months after the procedure unless they were already on
anticoagulation for other reasons. One patient with obstruc-
tion in the TAR was maintained on coumadin for four
months after the procedure because of the proximity of the
stent to the left common carotid artery.
Statistical analysis. Data are presented as the mean SD.
Comparison for individual parameters before and after
stenting were performed using the two-tailed paired t test.
Comparison between patients who had native CoA and
those with re-coarctation, as well as between those with
tubular versus discrete coarctation, was made using the
two-tailed unpaired t test for continuous-valued data. For
categorical data, chi-square analysis was used. Linear and
multiple regression analyses were performed to test the
effect of growth and age of the patients adjusting for variable
lengths of follow-up using SAS statistical software. A p
value 0.05 was considered statistically significant.
Follow-up. Clinical details, blood pressure data and results
of echocardiogram, chest X-ray, MRI and catheterization
were determined by retrospective chart review.
RESULTS
Initial results. The stents were implanted in the stenotic
area in 33 of 34 patients (97%) (Fig. 1). In one patient with
re-coarctation eight years after subclavian flap repair, a
16 mm HP balloon ruptured, and the partially inflated stent
migrated and was expanded without complications in the
right external iliac artery. No further therapy was attempted.
This was the only patient who did not have stent placement
for his coarctation. He had no complications upon
follow-up with MRI. In the 33 remaining patients in whom
the stents were placed across the site of obstruction, the
peak systolic pressure gradient decreased from 32 
12 mm Hg to 4 11 mm Hg (p 0.001) immediately after
Table 1. Characteristics of the Patients (n  34)
Men/women 25/9
Age (yrs) 16  8 (4–36)
Weight (kg) 56  23 (18–145)
Body surface area (m2) 1.5  0.3 (0.8–2.4)
Symptoms 10 (29%)
Hypertension 22 (65%)
Isolated CoA 7 (21%)
Associated cardiac defects 27 (79%)
Bicuspid aortic valve 13
VSD with/without repair 6
Left heart obstruction 10*
Isthmus/arch hypoplasia 9
Others 5
*Five patients had aortic stenosis; two had hypoplastic left heart syndrome and
underwent bidirectional Glenn shunt or Fontan procedure; one had Turner’s
syndrome, and two had Shone’s complex.
Stents were placed in 33/34 patients attempted.
CoA  coarctation of the aorta; VSD  ventricular septal defect.




After BA only 2 (6)
After surgery only 12 (35)
After both 7 (21)







*Stents were placed after 6  8 years from the last intervention. In three patients, the
obstruction was in the transverse aortic arch. †One patient had both subclavian flap
and arch aortoplasty repairs in the same surgery, and one patient had jump graft
bypassing the coarctation site and was included in the “native” group. Stents were
placed in 33/34 patients attempted.
BA  balloon angioplasty; CoA  coarctation of the aorta.
Abbreviations and Acronyms
BA  balloon angioplasty
CoA  coarctation of the aorta
DAo  descending aorta
ECMO  extracorporeal membrane oxygenation
HP  high pressure
LP  low pressure
MRI  magnetic resonance imaging
SBP  systolic blood pressure
TAR  transverse aortic arch
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stent implantation. The ratio of the final balloon diameter
to coarctation diameter before stent placement was 2.7 
1.9 (range: 1.4 to 12), while final balloon diameter to DAo
diameter ratio was 1.0  0.2 (range: 0.7 to 1.5). Although
10 patients had final balloon diameter/DAo diameter ratio
1, their final stent diameter/DAo diameter ratio remained
1 because larger balloons were necessary to expand the
stent adequately. The ratio of coarctation diameter to DAo
diameter increased by 50% from 0.46 0.16 to 0.92 0.16
(p  0.001). Balloons used had a mean diameter of 17 
2 mm (range: 12 to 20 mm), while the arterial sheaths used
ranged from 8F to 14F.
Suboptimal outcome. A 34-year-old patient had a 5-cm
long re-coarctation after surgical repair in childhood. Two
telescoping stents were placed but could not be expanded
adequately despite the use of single and double balloons
inflated up to 25 atms. The patient had a residual gradient
of 60 mm Hg and was referred for surgery.
Complications. Major complications (defined as those re-
quiring surgical treatment) occurred in two patients (6%),
and minor complications occurred in four patients (12%).
Major complications included a retroperitoneal hematoma
secondary to bleeding from the external iliac artery in a
16-year-old child because of high femoral artery puncture
and a fragment of ruptured balloon embolized to the left
axillary artery in another 19-year-old patient.
Minor complications included: additional stent place-
ment in the DAo distal to the coarctation site in two
Figure 1. Initial implantation of Palmaz 308 stent in a 15-year-old patient with native coarctation of the aorta and 18-month angiography follow-up. (A
and B) Initial postero-anterior and lateral angiography showed an 8-mm coarctation with a 35-mm Hg pressure difference. (C and D) The diameter
increased to 18 mm immediately after stent implantation. (E and F) Repeat angiography 18 months later shows no recurrent obstruction and no aneurysm.
There is some remodeling of the aorta with minimal neointimal proliferation.
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patients after the partially inflated stent migrated and had to
be fully expanded in the DAo. In one patient, the procedure
was aborted after the stent migrated and had to be inflated
in the right external iliac artery (as mentioned above).
Another patient developed a small femoral arteriovenous
fistula two weeks after the procedure with spontaneous
resolution. Acute dissection or aneurysm formation did not
occur in any of the patients.
Deaths. There were no deaths related to the procedure.
One 16-year-old patient with Shone’s complex who had a
documented influenza A sepsis and Adult Respiratory
Distress syndrome had stent placement for CoA and bal-
loon valvuloplasty of mitral stenosis to try to improve her
low output state before she was placed on extracorporeal
membrane oxygenation (ECMO). She died two weeks later
from complications related to ECMO.
Repeat catheterization and stent dilation. Four patients
underwent repeat cardiac catheterization 16  5 months
after their initial stent implantation (range 10 to 21
months). Two patients were catheterized for follow-up of
their stenting procedure, and the other two for pre-surgical
evaluation of additional cardiac defects. None of these
patients was found to have aneurysm formation, stent
displacement or fracture (Fig. 1). One patient had a recur-
rent peak gradient of 24 mm Hg across the stent secondary
to somatic growth and increased cardiac index without
intimal hyperplasia. He underwent successful stent dilation
from 13 to 17 mm using an 18-mm HP balloon with
reduction of the peak gradient to 8 mm Hg. Another
patient had stent implantation at 12 years of age (and
weight of 57 kg) for CoA using a 13-mm LP balloon.
Re-catheterization 16 months later (at weight of 70 kg)
showed a 10-mm Hg gradient across the stent, which was
eliminated as the stent was dilated from 11 to 14 mm using
an 18-mm HP balloon to accommodate somatic growth.
The other two patients had no gradient across the stent.
Follow-up procedure. The 31 patients who were success-
fully stented and alive were followed for 29  17 months
(median: 28 months, range: 5 to 81 months). Follow-up
blood pressure data are available for 28/31 patients. Two
patients had aberrant right subclavian arteries, and the
repair involved the left subclavian artery, while the third had
no recorded blood pressure after the procedure. Sphygmo-
manometric systolic blood pressure (SBP) gradient de-
creased from 39 18 mm Hg before stent placement to 4
6 mm Hg at follow-up (p  0.001), while SBP decreased
from 136  21mm Hg to 122  19 mm Hg at the last
follow-up (p  0.002). Doppler echocardiographic data are
available for 28/31 patients. Peak Doppler pressure gradient
decreased from 51  26 mm Hg before stent implantation
to 13  11 mm Hg at follow-up (p  0.001). A total of
22/31 patients (71%) were hypertensive and 13 (42%) were
on antihypertensive medications before stent implantation.
At their last follow-up visit, only 8/31 (26%) remain
hypertensive and on antihypertensive medications (p 
0.05), and all the patients are asymptomatic.
There was no evidence of recurrent coarctation, aneurysm
formation or stent displacement or fracture identified by
follow-up echocardiography and chest X-ray (in 30 pa-
tients), MRI (in 1 patient) or repeat catheterization (in 4
patients). There were no significant differences in the initial
or follow-up results between patients with native and those
with recurrent CoA or between patients with tubular versus
discrete coarctation. Linear and multiple regression analy-
ses, adjusting for the variable duration of follow-up, showed
no significant effect of age or body surface area on the
change in SBP (p 0.6 and 0.4, respectively), the change in
peak Doppler echocardiography gradient (p  0.3 and 0.9,
respectively) or the change in SBP cuff gradient (p  0.1
and 0.5, respectively).
Residual arch gradient. In 7/31 (23%) patients, a mild
gradient in the TAR of 5 to 20 mm Hg became unmasked
after the stent was successfully placed in the original
coarctation site, despite having no gradient in the TAR
before stent implantation. At follow-up, 3/7 continue to
have a mild gradient (20 mm Hg) and isthmus/arch
hypoplasia.
DISCUSSION
Balloon-expandable endovascular stents have been used in
various locations since the 1980’s (1–8,12–14). Stents sup-
port the integrity of the vessel wall after balloon dilation by
opposing the recoil of the elastic vascular stenosis and
reapplying the torn intima to the media. This minimizes the
extension of wall tears and subsequent dissection or aneu-
rysm formation that could occur after BA alone
(3,7,12,14,15). Acute aortic dissection and aneurysms can
develop in 1% to 4% and 4% to 11.5% of patients,
respectively, after BA (11,12,16–19). Stents provide a
homogenous framework for smooth endothelial growth
along the aortic wall that reduces the risk of thrombosis,
neointimal hyperplasia and subsequent restenosis (1).
Initial results. Stent implantation was performed in 33/34
patients catheterized with the intention to treat, and excel-
lent initial results occurred in 32 of 33 patients stented,
regardless to the type of their coarctation, comparable to
what has been previously reported (6,7,20–22). This is
considerably better than BA alone where suboptimal initial
results were reported in 19% to 25% of patients, especially in
tight coarctation sites (3.5 mm) and long segments of
narrowing (10–12,16,23,24).
Complications. Stent migration is a recognizable compli-
cation of stent placement (6,20,22). The use of the balloon-
in-balloon catheter (BIB, NuMED Inc.) may provide more
control of the inflation by using the better anchoring
mechanism of the inner smaller balloon that is inflated first.
Balloon rupture occurred in five patients, resulting in stent
migration in three, but the ruptured balloons were retrieved
successfully through the sheaths in four patients. Balloon
rupture can be minimized by using a balloon that has the
same length or slightly shorter than the stent and keeping
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the exchange wire as straight as possible during inflation, a
factor that could be more difficult to achieve in the TAR
than in the DAo or other locations.
Complications related to the arterial access were reported
in up to 19% of patients with CoA after BA or stent
placement (6,16,18–20). This is higher than the 6% (2/34)
in our study. The vascular complications in our study were
related to the femoral artery cannulation and could have
been prevented.
Stent re-dilation. Despite one report in animals of acute
aortic rupture and death upon attempted stent re-dilation
(25), several studies in animal models and in humans with
CoA have shown that stents can be further expanded to
accommodate somatic growth, up to three years after
implantation (3,7,8,13,22). Our experience is still limited
though in regards to the safety and long-term effects of
multiple stent expansions, especially in younger patients. It
is also unknown to what diameter a stent can be safely
expanded at initial implantation. The diameter of the
stented coarctation segment should not generally exceed the
diameter of the isthmus and/or DAo at the level of the
diaphragm. In patients with hypoplastic isthmus or tight
coarctation (4 mm), the stent should be expanded to a
reasonable diameter (12 to 14 mm) and then re-dilated in
six months.
Follow-up. We had no cases of aneurysm formation de-
tected by echocardiography, repeat catheterization or MRI.
Echocardiography, however, may be less sensitive than
angiography, spiral computed tomography or MRI in de-
tecting aneurysms after stent placement. Magnetic reso-
nance imaging has a limited role in CoA after stent
placement since the metallic artifact (or noise) prevents
detailed evaluation of the aortic segment within the stent,
despite adequate visualization of the aorta proximal and
distal to the stent. Magee et al. (20) reported one patient
with a small aneurysm detected by angiography, which
remained stable for two years upon follow-up with serial
computed tomograms.
Residual arch obstruction. Stents can be very effective in
relieving arch obstruction. Three patients had obstruction in
the TAR and had no residual gradient either initially after
stent implantation or at follow-up. On the other hand, the
relief of distal obstruction in the DAo unmasked TAR
stenosis in three patients who also have isthmus or TAR
hypoplasia and continue to have a mild gradient at follow-
up. Isthmus and arch hypoplasia were shown to be risk
factors for early and late failure after BA in CoA
(10,11,19,23,24,26).
Study limitations. The use of stents in CoA remains
limited to older children and adults because of the large
delivery systems required and the need of multiple stent
expansions to accommodate growth. It is unclear whether
the noncompliant aortic stents would alter the flow pattern
in a way that contributes to the occurrence of late re-stenosis
and aneurysm formation in the growing aorta. We still lack
adequate long-term follow-up of these patients.
Conclusions. Coarctation of the aorta can be successfully
and safely managed with endovascular stents. They provide
an alternative form of therapy in patients with native or
recurrent CoA in the short and intermediate terms. Ques-
tions remain to be answered on the impact of stents on
blood flow dynamics and the best management in patients
with arch hypoplasia. Long-term follow-up is, thus, needed.
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